EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases

Patients' inclusion criteria: * Group A: Patients with EBV driven lymphomas (e.g., NK/T-cell lymphoma), with EBV complications (e.g. HLH, CAEBV) or patients with primary immunodeficiency disorders with high risk for EBV complications (e.g. SCID) with planned allogeneic HCT * Group B: EBV-driven PTLD that develop after a HCT or SOT For both groups: * All age groups * Negative pregnancy test in female patients of childbearing potential. * Signed written informed consent of patient or/and parents Patients' exclusion criteria: * Patients receiving anti-thymocyte globulin or Campath within 28 days of infusion * Patients with active, acute GvHD grades III-IV * Previous severe reaction to dimethylsulfoxide (DMSO) Donors' inclusion criteria: * EBV positive serology (VCA and Epstein-Barr nuclear antigen (EBNA) immunoglobulin G (IgG) positive) * Detectable interferon (IFN)-y-secreting T cells (\>100 SFC/10e6 PBMC) measured by Elispot to the EBV consensus peptide pool * Suitability for blood or HCT donation meeting requirements of local institutional guidelines * An informed consent for EBV Tscm CTL manufacturing * Age \> 18 years Donors' exclusion criteria: * Detectable IFN-y-secreting T-cells \<100 spot-forming cell (SFC)/10e6 PBMC measured by Elispot to EBV select * Unwilling and/or unable to donate, according to the donor center